{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:47:30Z","timestamp":1790790450882,"version":"4.1.0"},"reference-count":169,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Berta Kamprad Foundation, Sweden"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Malignant melanoma is a very aggressive skin cancer, characterized by a heterogeneous nature and high metastatic potential. The incidence of melanoma is continuously increasing worldwide, and it is one of the most common cancers in young adults. In the past twenty years, our understanding of melanoma biology has increased profoundly, and disease management for patients with disseminated disease has improved due to the emergence of immunotherapy and targeted therapy. However, a significant fraction of patients relapse or do not respond adequately to treatment. This can partly be explained by the complex signaling between the tumor and its microenvironment, giving rise to melanoma phenotypes with different patterns of disease progression. This review focuses on the key aspects and complex relationship between pathogenesis, genetic abnormalities, tumor microenvironment, cellular plasticity, and metabolic reprogramming in melanoma. By acquiring a deeper understanding of the multifaceted features of melanomagenesis, we can reach a point of more individualized and patient-centered disease management and reduced costs of ineffective treatments.<\/jats:p>","DOI":"10.3390\/ijms241814403","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T21:08:36Z","timestamp":1695330516000},"page":"14403","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Exploring the Complex and Multifaceted Interplay between Melanoma Cells and the Tumor Microenvironment"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9479-423X","authenticated-orcid":false,"given":"Magdalena","family":"Kuras","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Lund University, 221 00 Lund, Sweden"},{"name":"Section for Clinical Chemistry, Department of Translational Medicine, Lund University, 205 02 Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1991.tb37758.x","article-title":"Cell lineage and cell migration in the neural crest","volume":"615","author":"Lallier","year":"1991","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","article-title":"Intratumor and Intertumor Heterogeneity in Melanoma","volume":"10","author":"Grzywa","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Coricovac, D., Dehelean, C., Moaca, E.A., Pinzaru, I., Bratu, T., Navolan, D., and Boruga, O. (2018). Cutaneous Melanoma-A Long Road from Experimental Models to Clinical Outcome: A Review. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061566"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14740\/wjon1349","article-title":"Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management","volume":"12","author":"Naik","year":"2021","journal-title":"World J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/1011-1344(91)80147-A","article-title":"Photoprotection by melanin","volume":"9","author":"Kollias","year":"1991","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrm2258","article-title":"Melanosomes--dark organelles enlighten endosomal membrane transport","volume":"8","author":"Raposo","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1046\/j.1523-1747.1998.00435.x","article-title":"Human melanocytes and keratinocytes exposed to UVB or UVA in vivo show comparable levels of thymine dimers","volume":"111","author":"Young","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/CMR.0000000000000857","article-title":"Ultraviolet A radiation exposure and melanoma: A review","volume":"32","author":"Fadadu","year":"2022","journal-title":"Melanoma Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9985","DOI":"10.3390\/ijms24129985","article-title":"Primary Undifferentiated\/Dedifferentiated Cutaneous Melanomas&mdash;A Review on Histological, Immunohistochemical, and Molecular Features with Emphasis on Prognosis and Treatment","volume":"24","author":"Dumitru","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3892\/etm.2022.11329","article-title":"Histopathological evaluation of cutaneous malignant melanoma: A retrospective study","volume":"23","author":"Avino","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lopes, J., Rodrigues, C.M.P., Gaspar, M.M., and Reis, C.P. (2022). Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers, 14.","DOI":"10.3390\/cancers14194652"},{"key":"ref_16","first-page":"13","article-title":"Diagnostic and prognostic biomarkers in melanoma","volume":"7","author":"Weinstein","year":"2014","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2559.2000.00894.x","article-title":"Morphological and immunophenotypic variations in malignant melanoma","volume":"36","author":"Banerjee","year":"2000","journal-title":"Histopathology"},{"key":"ref_18","first-page":"e38693","article-title":"The Role of Biomarkers in the Diagnosis and Prognosis of Different Stages of Melanoma","volume":"15","author":"Nwafor","year":"2023","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cazzato, G., Mangialardi, K., Falcicchio, G., Colagrande, A., Ingravallo, G., Arezzo, F., Giliberti, G., Trilli, I., Loizzi, V., and Lettini, T. (2022). Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study. Genes, 13.","DOI":"10.3390\/genes13030545"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e4332","DOI":"10.1097\/MD.0000000000004332","article-title":"Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis","volume":"95","author":"Sondermann","year":"2016","journal-title":"Medicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12105-023-01536-y","article-title":"Top 10 Differential Diagnoses for Desmoplastic Melanoma","volume":"17","author":"Singh","year":"2023","journal-title":"Head Neck Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME Expression in Melanocytic Tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/ajcp\/aqab200","article-title":"Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis","volume":"157","author":"Ricci","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/bjc.2016.187","article-title":"The cancer\/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas","volume":"115","author":"Nettersheim","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/PAS.0000000000001492","article-title":"Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_27","first-page":"1071","article-title":"Cutaneous melanoma: From pathogenesis to therapy (Review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.08.038","article-title":"Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome","volume":"74","author":"Soura","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1093\/hmg\/ddu312","article-title":"Most common \u2018sporadic\u2019 cancers have a significant germline genetic component","volume":"23","author":"Lu","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2015-103150","article-title":"Melanoma genetics","volume":"53","author":"Read","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jnci\/djs221","article-title":"Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers","volume":"104","author":"Mukherjee","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"583748","DOI":"10.1155\/2010\/583748","article-title":"From melanocyte to metastatic malignant melanoma","volume":"2010","author":"Bandarchi","year":"2010","journal-title":"Dermatol. Res. Pract."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2147\/CMAR.S155283","article-title":"MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: A pooled analysis from the M-SKIP project","volume":"10","author":"Tagliabue","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.ejca.2010.01.027","article-title":"MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis","volume":"46","author":"Fargnoli","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.molcel.2013.08.010","article-title":"MC1R is a potent regulator of PTEN after UV exposure in melanocytes","volume":"51","author":"Cao","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.18632\/oncotarget.1892","article-title":"Pathways and therapeutic targets in melanoma","volume":"5","author":"Shtivelman","year":"2014","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bbamcr.2016.01.025","article-title":"Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling","volume":"1863","author":"Paluncic","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/474171a","article-title":"Cyclin D1 multitasks","volume":"474","author":"Bartek","year":"2011","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","article-title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi","volume":"436","author":"Michaloglou","year":"2005","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jid.2017.05.030","article-title":"Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, a Candidate Melanoma Suppressor Function","volume":"137","author":"MacKenzie","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/72799","article-title":"A genome-wide survey of RAS transformation targets","volume":"24","author":"Zuber","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fonc.2015.00031","article-title":"Phenotype switching in melanoma: Implications for progression and therapy","volume":"5","author":"Li","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semcancer.2003.09.015","article-title":"Oncogenic Ras and its role in tumor cell invasion and metastasis","volume":"14","author":"Campbell","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: A new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches","volume":"16","author":"Maiello","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102238","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: Towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1158\/0008-5472.CAN-07-5867","article-title":"Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development","volume":"68","author":"Cheung","year":"2008","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"Braf(V600E) cooperates with Pten loss to induce metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1101\/gad.187252.112","article-title":"Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis","volume":"26","author":"Vredeveld","year":"2012","journal-title":"Genes Dev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1101\/gad.450107","article-title":"Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development","volume":"21","author":"Delmas","year":"2007","journal-title":"Genes Dev."},{"key":"ref_55","first-page":"566","article-title":"MicroRNA-374a activates Wnt\/\u03b2-catenin signaling to promote breast cancer metastasis","volume":"123","author":"Cai","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and Melanoma: Biological Insights and Clinical Implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3892\/or.2016.4660","article-title":"Role of the tumor microenvironment in tumor progression and the clinical applications (Review)","volume":"35","author":"Yuan","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kimm, M.A., Klenk, C., Alunni-Fabbroni, M., K\u00e4stle, S., Stechele, M., Ricke, J., Eisenbl\u00e4tter, M., and Wildgruber, M. (2021). Tumor-Associated Macrophages-Implications for Molecular Oncology and Imaging. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040374"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/his.13489","article-title":"The tumour-stroma ratio in colon cancer: The biological role and its prognostic impact","volume":"73","author":"Sandberg","year":"2018","journal-title":"Histopathology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fonc.2020.00851","article-title":"Metabolic Traits in Cutaneous Melanoma","volume":"10","author":"Neagu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1074\/jbc.M117.786442","article-title":"Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition","volume":"292","author":"Trotta","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.bbabio.2017.02.001","article-title":"Cancer metabolism in space and time: Beyond the Warburg effect","volume":"1858","author":"Danhier","year":"2017","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/cr.2017.155","article-title":"Mitochondrial metabolism and cancer","volume":"28","author":"Porporato","year":"2018","journal-title":"Cell Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Roberts, E.R., and Thomas, K.J. (2013). The role of mitochondria in the development and progression of lung cancer. Comput. Struct. Biotechnol. J., 6.","DOI":"10.5936\/csbj.201303019"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1046102","DOI":"10.3389\/fonc.2022.1046102","article-title":"Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","article-title":"Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence","volume":"179","author":"Harel","year":"2019","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41417-021-00318-4","article-title":"Cancer-associated fibroblasts: Overview, progress, challenges, and directions","volume":"28","author":"Ping","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fonc.2015.00224","article-title":"Targeting ECM Disrupts Cancer Progression","volume":"5","author":"Venning","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Martinez-Vidal, L., Murdica, V., Venegoni, C., Pederzoli, F., Bandini, M., Necchi, A., Salonia, A., and Alfano, M. (2021). Causal contributors to tissue stiffness and clinical relevance in urology. Commun. Biol., 4.","DOI":"10.1038\/s42003-021-02539-7"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"922","DOI":"10.18632\/oncotarget.26644","article-title":"Tumor stroma as contributing factor in the lymph node metastases process?","volume":"10","author":"Mesker","year":"2019","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00428-018-2408-z","article-title":"Scoring the tumor-stroma ratio in colon cancer: Procedure and recommendations","volume":"473","author":"Morreau","year":"2018","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrc2468","article-title":"Hypoxia, HIF1 and glucose metabolism in the solid tumour","volume":"8","author":"Denko","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/febs.16021","article-title":"Epithelial-to-mesenchymal-like transition events in melanoma","volume":"289","author":"Pedri","year":"2022","journal-title":"FEBS J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"763992","DOI":"10.3389\/fonc.2021.763992","article-title":"Malignant Melanoma With Neuroendocrine Differentiation: A Case Report and Literature Review","volume":"11","author":"Cham","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/jcmm.13082","article-title":"The plasticity of germ cell cancers and its dependence on the cellular microenvironment","volume":"21","author":"Nettersheim","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1755-148X.2010.00757.x","article-title":"Cancer stem cells versus phenotype-switching in melanoma","volume":"23","author":"Hoek","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1101\/gad.329771.119","article-title":"Melanoma plasticity and phenotypic diversity: Therapeutic barriers and opportunities","volume":"33","author":"Rambow","year":"2019","journal-title":"Genes Dev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1038\/ncomms7683","article-title":"Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state","volume":"6","author":"Verfaillie","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1242\/dev.123729","article-title":"The melanocyte lineage in development and disease","volume":"142","author":"Mort","year":"2015","journal-title":"Development"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1158\/0008-5472.CAN-04-0731","article-title":"Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas","volume":"64","author":"Hoek","year":"2004","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2017.01.029","article-title":"Potential therapeutic targets of epithelial-mesenchymal transition in melanoma","volume":"391","author":"Pearlman","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3851576","DOI":"10.1155\/2019\/3851576","article-title":"Epithelial-Mesenchymal Transition in Skin Cancers: A Review","volume":"2019","author":"Hodorogea","year":"2019","journal-title":"Anal. Cell. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e156577","DOI":"10.1172\/jci.insight.156577","article-title":"DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype","volume":"7","author":"Sanna","year":"2022","journal-title":"JCI Insight"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","article-title":"Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature","volume":"19","author":"Hoek","year":"2006","journal-title":"Pigment Cell Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.1158\/0008-5472.CAN-08-0301","article-title":"Tbx3 represses E-cadherin expression and enhances melanoma invasiveness","volume":"68","author":"Rodriguez","year":"2008","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"756001","DOI":"10.3389\/fonc.2021.756001","article-title":"Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Pagliuca, C., Di Leo, L., and De Zio, D. (2022). New Insights into the Phenotype Switching of Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14246118"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Hossain, S.M., and Eccles, M.R. (2023). Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021601"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","article-title":"Mechanisms of immune activation and regulation: Lessons from melanoma","volume":"22","author":"Kalaora","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","article-title":"Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment","volume":"59","author":"Marzagalli","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pathol.2015.12.006","article-title":"Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy","volume":"48","author":"Lee","year":"2016","journal-title":"Pathology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"215925","DOI":"10.1016\/j.canlet.2022.215925","article-title":"TGF-\u03b2 signaling networks in the tumor microenvironment","volume":"550","author":"Chan","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12016-019-08753-w","article-title":"Role of Mast Cells in Shaping the Tumor Microenvironment","volume":"58","author":"Komi","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"668349","DOI":"10.3389\/fonc.2021.668349","article-title":"CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion","volume":"11","author":"Gunaydin","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41590-022-01291-2","article-title":"Eosinophil\u2013lymphocyte interactions in the tumor microenvironment and cancer immunotherapy","volume":"23","author":"Rothenberg","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.phrs.2017.07.006","article-title":"Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance","volume":"123","author":"Pulluri","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","article-title":"Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response","volume":"14","author":"Fu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade","volume":"175","author":"Shah","year":"2018","journal-title":"Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1231734","DOI":"10.3389\/fimmu.2023.1231734","article-title":"HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy","volume":"14","author":"Bravo","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","article-title":"Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis","volume":"19","author":"Tsujikawa","year":"2017","journal-title":"Cell Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat. Methods"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Hsieh, W.-C., Budiarto, B.R., Wang, Y.-F., Lin, C.-Y., Gwo, M.-C., So, D.K., Tzeng, Y.-S., and Chen, S.-Y. (2022). Spatial multi-omics analyses of the tumor immune microenvironment. J. Biomed. Sci., 29.","DOI":"10.1186\/s12929-022-00879-y"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4143\/crt.2019.195","article-title":"High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment","volume":"52","author":"Koh","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1089265","DOI":"10.3389\/fonc.2022.1089265","article-title":"Editorial: Multiplexed image analysis for translational research project applications","volume":"12","author":"Capelozzi","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41374-021-00653-y","article-title":"Establishing standardized immune phenotyping of metastatic melanoma by digital pathology","volume":"101","author":"Sobottka","year":"2021","journal-title":"Lab. Investig. A J. Tech. Methods Pathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/pcmr.12926","article-title":"The tumour immune landscape and its implications in cutaneous melanoma","volume":"34","author":"Attrill","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Kuczkiewicz-Siemion, O., Sok\u00f3\u0142, K., Puton, B., Borkowska, A., and Szumera-Cie\u0107kiewicz, A. (2022). The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. Cancers, 14.","DOI":"10.3390\/cancers14153833"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cac2.12023","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Sun, Z., Nyberg, R., Wu, Y., Bernard, B., and Redmond, W.L. (2021). Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247238"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ugolini, F., Pasqualini, E., Simi, S., Baroni, G., and Massi, D. (2022). Bright-Field Multiplex Immunohistochemistry Assay for Tumor Microenvironment Evaluation in Melanoma Tissues. Cancers, 14.","DOI":"10.3390\/cancers14153682"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Yaseen, Z., Gide, T.N., Conway, J.W., Potter, A.J., Quek, C., Hong, A.M., Long, G.V., Scolyer, R.A., and Wilmott, J.S. (2022). Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.810858"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: Macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1158\/1078-0432.CCR-22-2657","article-title":"Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s40425-019-0797-4","article-title":"The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors","volume":"7","author":"Massi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_127","first-page":"1","article-title":"Melanoma\u2014Clinical, dermatoscopical, and histopathological morphological characteristics","volume":"22","author":"Situm","year":"2014","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.hoc.2009.03.013","article-title":"The classification of cutaneous melanoma","volume":"23","author":"Duncan","year":"2009","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: Implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome","volume":"16","author":"Jonsson","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1158\/1078-0432.CCR-12-0343","article-title":"Molecular profiling reveals low- and high-grade forms of primary melanoma","volume":"18","author":"Harbst","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward Minimal Residual Disease-Directed Therapy in Melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/pcmr.13041","article-title":"Protein-based classification of melanoma differentiation subtypes","volume":"35","author":"Lim","year":"2022","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","article-title":"Phenotype plasticity as enabler of melanoma progression and therapy resistance","volume":"19","author":"Arozarena","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41556-020-0547-3","article-title":"Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma","volume":"22","author":"Wouters","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbcan.2019.02.002","article-title":"Many ways to resistance: How melanoma cells evade targeted therapies","volume":"1871","author":"Kozar","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment-Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1200\/JCO.2022.40.16_suppl.9522","article-title":"Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067","volume":"40","author":"Hodi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.semcancer.2019.08.001","article-title":"Immune-checkpoint inhibitors for the treatment of metastatic melanoma: A model of cancer immunotherapy","volume":"59","author":"Queirolo","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41401-022-00953-z","article-title":"Immune-based combination therapy to convert immunologically cold tumors into hot tumors: An update and new insights","volume":"44","author":"Ni","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"adv00141","DOI":"10.2340\/00015555-3496","article-title":"Cutaneous Melanoma-A Review of Systemic Therapies","volume":"100","author":"Lee","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/1078-0432.CCR-14-0567","article-title":"Genetic evolution of T-cell resistance in the course of melanoma progression","volume":"20","author":"Sucker","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e120360","DOI":"10.1172\/jci.insight.120360","article-title":"Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement","volume":"3","author":"Johnson","year":"2018","journal-title":"JCI Insight"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1158\/0008-5472.CAN-14-2956","article-title":"Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity","volume":"75","author":"Donia","year":"2015","journal-title":"Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1158\/0008-5472.CAN-08-1053","article-title":"Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells","volume":"68","author":"Goodall","year":"2008","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1755-148X.2011.00849.x","article-title":"Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor","volume":"24","author":"Boyle","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1038\/onc.2011.33","article-title":"Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway","volume":"30","author":"Thurber","year":"2011","journal-title":"Oncogene"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Krijgsman","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"168","author":"Hugo","year":"2017","journal-title":"Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-13-0005","article-title":"Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2","volume":"3","author":"Marchbank","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/cr.2008.303","article-title":"Transcriptional and signaling regulation in neural crest stem cell-derived melanocyte development: Do all roads lead to Mitf?","volume":"18","author":"Hou","year":"2008","journal-title":"Cell Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Beiu, C., Giurcaneanu, C., Grumezescu, A.M., Holban, A.M., Popa, L.G., and Mihai, M.M. (2020). Nanosystems for Improved Targeted Therapies in Melanoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020318"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Verma, J., Warsame, C., Seenivasagam, R.K., Katiyar, N.K., Aleem, E., and Goel, S. (2023). Nanoparticle-mediated cancer cell therapy: Basic science to clinical applications. Cancer Metastasis Rev., 1\u201327.","DOI":"10.1007\/s10555-023-10086-2"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejpb.2023.02.002","article-title":"Nanodelivery systems for cutaneous melanoma treatment","volume":"184","author":"Pereira","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: A phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Combination therapy with CAR T cells and oncolytic viruses: A new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Kasakovski, D., Skrygan, M., Gambichler, T., and Susok, L. (2021). Advances in Targeting Cutaneous Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13092090"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nm.2172","article-title":"Lipid accumulation and dendritic cell dysfunction in cancer","volume":"16","author":"Herber","year":"2010","journal-title":"Nat. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature21379","article-title":"Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism","volume":"543","author":"Pan","year":"2017","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/14403\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:12Z","timestamp":1760129712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/14403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":169,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241814403"],"URL":"https:\/\/doi.org\/10.3390\/ijms241814403","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}